Arcus Biosciences (RCUS) Income from Continuing Operations: 2017-2025
Historic Income from Continuing Operations for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -$135.0 million.
- Arcus Biosciences' Income from Continuing Operations fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
- Per Arcus Biosciences' latest filing, its Income from Continuing Operations stood at -$135.0 million for Q3 2025, which was down 20.54% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' Income from Continuing Operations' 5-year high stood at $279.5 million during Q4 2021, with a 5-year trough of -$135.0 million in Q3 2025.
- In the last 3 years, Arcus Biosciences' Income from Continuing Operations had a median value of -$86.5 million in 2023 and averaged -$83.7 million.
- Examining YoY changes over the last 5 years, Arcus Biosciences' Income from Continuing Operations showed a top increase of 637.62% in 2021 and a maximum decrease of 4,379.64% in 2021.
- Quarterly analysis of 5 years shows Arcus Biosciences' Income from Continuing Operations stood at $279.5 million in 2021, then crashed by 123.97% to -$67.0 million in 2022, then fell by 20.90% to -$81.0 million in 2023, then decreased by 16.05% to -$94.0 million in 2024, then tumbled by 46.74% to -$135.0 million in 2025.
- Its last three reported values are -$135.0 million in Q3 2025, -$112.0 million for Q1 2025, and -$94.0 million during Q4 2024.